

ADHD medicatie		Bewijskracht niveau	literatuur
< 6 jaar	Altijd off label		
Methylfenidaat IR	Altijd off label	2	<p>Coghill, D. & S. Seth. (2006). Osmotic, controlled-release methylphenidate for the treatment of ADHD. <i>Expert Opin. Pharmacother</i>, 7(15):2119-2138.</p> <p>Ghuman, J. & H. Ghuman. (2013). Pharmacologic Intervention for Attention-Deficit Hyperactivity Disorder in Preschoolers, <i>Pediatr Drugs</i>, 15(1): 1-8.</p> <p>Ghuman J.K., Aman, M.G., Ghuman, H.S., et al. (2009). Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. <i>J Child Adolesc Psychopharmacol</i>, 19(2):155-166.</p> <p>Greenhill, L.L, Posner, K., Vaughan, B.S. & C.J. Kratochvil. (2008). Attention Deficit Hyperactivity Disorder in Preschool Children, <i>Child Adolesc Psychiatric Clin N Am</i>, 17:347–366.</p> <p>Greenhill, L., Kollins, S., Abikoff, H., McCracken, J. et al. (2006). PATS studie, Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. <i>J. Am. Acad. Child. Adolesc. Psychiatry</i>, 45(11):1284-1293.</p> <p>Kratochvil, C.J, Greenhill, L., March, J., Burke, W. & B. Vaughan (2004), The Role of Stimulants in the Treatment of Preschool Children with Attention-Deficit Hyperactivity Disorder, <i>CNS Drugs</i>, 18 (14): 957-966.</p> <p>Valdizan-Uson, J.R., Cánovas-Martínez, A., De Lucas-Taracena, M.T., Díaz-Atienza, F. et al. (2013). Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study, <i>Neuropsychiatric Disease and Treatment</i>, 9: 211-218. (observationeel).</p>
Concerta R	Altijd off label	4	Coghill, D. & S. Seth. (2006). Review, Osmotic, controlled-release methylphenidate for the treatment of ADHD. <i>Expert Opin. Pharmacother</i> , 7(15):2119-2138.
Equasym XL R	Altijd off label	4	Geen studies gedaan, geen literatuur.

Medikinet CR R	Altijd off label	4	Geen literatuur gevonden.
Dexamfetamine	Altijd off label	4	Geen literatuur gevonden.
Atomoxetine	Altijd off label	3	<p>Ghuman J.K., Aman, M.G., Ghuman, H.S., et al. (2009). Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. <i>J Child Adolesc Psychopharmacol</i>, 19(2):155-166.</p> <p>Kratochvil, C.J., Vaughan, B.S., Stoner, J.A., et al. (2011). A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. <i>Pediatrics</i>, 127(4):e862-e868.</p> <p>Kratochvil, C.J., Vaughan, B.S., Mayfield-Jorgensen, M.L., et al. (2007). A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder. <i>J Child Adolesc Psychopharmacol</i>, 17(2):175-185.</p> <ul style="list-style-type: none"> • Another open-label pilot study assessed treatment with atomoxetine in 12 preschool children (ages 3 to 5 years) with ADHD (Ghuman, 2009). • An open-label pilot study assessed the effectiveness and tolerability of atomoxetine during acute treatment of ADHD in 5- and 6-year-olds (n=22) (Kratochvil, 2007). • Atomoxetine was evaluated in an 8-week, randomized, double-blind, placebo-controlled study in 5- and 6-year-old children (n=93) with ADHD (Kratochvil, 2011).
6-18 jaar	geregistreerd		
Methylfenidaat IR	+	1	<p>Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., et al. (2006). Long-acting medications for the hyperkinetic disorders A systematic review and European treatment guideline. <i>Eur Child Adolesc Psychiatry</i>. 2006, 15(8):476-95.</p> <p>Donagh, M.S., Peterson, K., Thakurta, S. & A. Low. (2011). Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder. <i>Oregon Health & Science University Portland</i>.</p>

			Keen, D. & I. Hadjickoumi. (2011). ADHD in children and adolescents. <i>Clin Evid (Online)</i> pii: 0312.
Concerta R	+	1	<p>Coghill, D. & S. Seth. (2006). Osmotic, controlled-release methylphenidate for the treatment of ADHD. <i>Expert Opin. Pharmacother</i>, 7(15):2119-2138.</p> <p>Zie ook reviews onder Equasym XL.</p>
Equasym XL R	+	1	<p>Dirksen, S.J., D'Imperio, J.M., Birdsall, D., Hatch, S.J. (2002). A postmarketing clinical experience study of Metadate® CD. <i>Curr Med Res Opin</i>, 18(7):371-380.</p> <p>Döpfner, M., Görtz-Dorten, A., Breuer, D., Rothenberger, A. (2011). An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. <i>Eur Child Adolesc Psychiatry</i>, 20(2):S243-55.</p> <p>Findling, R.L., Quinn, D., Hatch, S.J., Cameron, S.J. & H.H. DeCory. (2006). Comparison of the clinical efficacy of twice-daily Ritalin® and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder. <i>Eur Child Adolesc Psychiatry</i>, 15: 450-459.</p> <p>Greenhill, L.L., Findling, R.L. & J.M. Swanson. (2002). A Double-Blind, Placebo-Controlled Study of Modified-Release Methylphenidate in Children With Attention Deficit/Hyperactivity Disorder. <i>Pediatrics</i>, 109;e39.</p> <p>Swanson, J.M., Wigal, S.B., Wigal, T., Sonuga-Barke, E., Greenhill, L.L. et al. (2004). A comparison of Once-Daily Extended-Release Methylphenidate Formulations in Children with Attention-Deficit/Hyperactivity Disorder in the Laboratory School (The Comacs Study). <i>Pediatrics</i>, 113 (3); 206-216</p> <p><u>Reviewartikelen</u></p> <ul style="list-style-type: none"> • Anderson, V.R. & G.M. Keating. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder. <i>Paediatr Drugs</i>, 8(5):319-33. • Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., et al. (2006). Long-

			<p>acting medications for the hyperkinetic disorders A systematic review and European treatment guideline. <i>Eur Child Adolesc Psychiatry</i>. 2006, 15(8):476-95.</p> <ul style="list-style-type: none"> • Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M. et al. (2011). European guidelines on managing adverse effects of medication for ADHD. <i>Eur Child Adolesc Psychiatry</i>, 20(1):17-37. • Graham, J. & D. Coghill. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. <i>CNS Drugs</i>, 22(3):213-37. • Takon, I. (2011). Clinical use of a modified release methylphenidate in the treatment of childhood attention deficit hyperactivity disorder. <i>Annals of General Psychiatry</i>, 10:25. • Harpin, V.A. (2008). Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance. <i>Arch. Dis. Child. Ed. Pract.</i>, 93;58-65.
Medikinet CR R	+	1	<p>Döpfner, M., Gerber, W.D., Banaschewski, T., Breuer, D., Freisleder, F.J. et al. (2004). A comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. <i>Eur Child Adolesc Psychiatry</i>, 13(1): 193–101.</p> <p>Döpfner, M., Banaschewski, T., Schmidt, J., Uebel, H., Schmeck, K., et al. (2003). Langzeitwirksames Methylphenidat bei Kindern mit Aufmerksamkeits- Hyperaktivitätsstörungen, <i>Nervenheilkunde</i>, 22:85–92.</p> <p>Keen, D. & I. Hadjikhouri. (2011). ADHD in children and adolescents. <i>Clin Evid</i> (Online) pii: 0312.</p> <p>Donagh, M.S., Peterson, K., Thakurta, S. & A. Low. (2011). Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder. <i>Oregon Health & Science University Portland</i>.</p>
Dexamfetamine	Off label	1	Keen, D. & I. Hadjikhouri. (2011). ADHD in children and adolescents. <i>Clin Evid</i> (Online) pii: 0312.

			Verwijst naar meer reviews.
Atomoxetine	+	1	<p>Bushe, C.J. & C.N. Savill. (2013). Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: Focus on clinical efficacy and safety. <i>J Psychopharmacol</i>. [Epub ahead of print].</p> <p>Bushe C.J. & C.N. Savill (2011). Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Systematic Review of Review Papers 2009–2011. An Update for Clinicians. <i>J Central Nervous System Disease</i>, 3;209–217.</p> <p>Garnock-Jones, K.P. & G.M. Keating (2009). Atomoxetine. A review of its Use in Attention-Deficit Hyperactivity Disorder in Children and Adolescents, <i>Pediatr. Drugs</i> 2009; 11(3): 203-226.</p> <p>Alle onafhankelijk die zijn gevonden waarbij Strattera met methylfenidaat is vergeleken:</p> <ul style="list-style-type: none"> • Hanwella, R., Senanayake, M., de Silva, V. (2011). Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis, <i>BMC Psychiatry</i>, 11:176. • Yang, L. (2011). Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial, <i>Int J Neuropsychopharmacol</i>, 15(1):15-26. • Yildiz, O. (2011). Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. <i>Child Psychiatry Hum Dev</i>, 42(3):257-69. <p>“Afhankelijke” studies</p> <ul style="list-style-type: none"> • Hazell, P.L., Kohn, M.R., Dickson, R., Walton, R.J., Granger, R.E, et al. (2011). Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. <i>J Atten Disord</i>, 15(8):674-83. • Study I (HFBE): Kratochvil, C.J., Heligenstein, J.H., Dittmann, R., Spencer, T.J., Biederman, J., et al. (2002). Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial, <i>J Am Acad Child Adolesc Psychiatry</i>, 41(7):776-84. • Study IV (LYBI): Newcorn J.H., Kratochvil, C.J., Allen, A.J., Casat, C.D. Dustin, D.Ruff, et al.(2008). Atomoxetine and osmotically released methylphenidate for the treatment of

			<p>attention deficit hyperactivity disorder: acute comparison and differential response. <i>Am J Psychiatry</i>;165(6):721-30.</p> <ul style="list-style-type: none"> • Study II (LYAV): Sangal, R.B., Owens, J., Allen, A.J., Sutton, V. et al. (2006). Effects of atomoxetine and methylphenidate on sleep in children with ADHD. <i>Sleep</i>, 29(12):1573-85. • Study III (LYBR): Wang, Y., Zheng, Y., Du, Y., Song, D.H., Shin, Y.J., et al. (2007). Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. <i>Aust N Z J Psychiatry</i>, 41(3):222-30. • Study IV (LYBI): Newcorn J.H., Kratochvil, Allen, Al. Casat, C., et al. (2008). Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. <i>Am J Psychiatry</i>,165(6):721-30.
TCA Nortriptyline	Off label	3	<p>Prince, J.B., Wilens, T.E., Biederman, J., Spencer, T.J., Millstein, R., et al. (2000). A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder, <i>J Child Adolesc Psychopharmacol</i>,10(3):193-204.</p> <p>Saul, R.C. (1958). Letters to the editor: Nortriptyline in Attention Deficit Disorder. <i>Clinical Neuropharmacology</i>,8(4), 382-384.</p> <p>Wilens, T.E., Biederman, J., Geist, D.E., Steingard, R., Spencer, T. (1993). Nortriptyline in the treatment of ADHD: a chart review of 58 cases, <i>J Am Acad Child Adolesc Psychiatry</i>, 32: 343-349.</p>
Clonidine	Off label	2-3	<p>Keen, D. & I. Hadjikhouri. (2011). ADHD in children and adolescents. <i>Clin Evid (Online)</i> pii: 0312.</p> <p>Donagh, M.S., Peterson, K., Thakurta, S. & A. Low. (2011). Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder. <i>Oregon Health & Science University Portland</i>.</p> <p>Childress, A.C. & F.R. Sallee (2012). Revisiting Clonidine: an Innovative Add-on Option for Attention-Deficit/Hyperactivity Disorder, <i>Drugs of today</i>, 48(3): 207:217.</p> <p>Connor, D.F., Fletcher, K.E. & J.M. Swanson. (1999). A Meta-Analysis of Clonidine for Symptoms of Attention-Deficit Hyperactivity Disorder. <i>J. Am. Acad. Child. Adolesc. Psychiatry</i>, 38(12): 1551-1559.</p>

			Sallee, F., Connor, D.F. & J.H. Newcorn (2013). A Review of the Rationale and Clinical Utilization of α_2 -Adrenoceptor Agonists for the Treatment of Attention-Deficit/Hyperactivity and Related Disorders, <i>MD2 Journal of Child and Adolescent Psychopharmacology</i> , 23(5): 308-319.
Atomoxetine en methylfenidaat	Off label voor deze combinatie	3	Treuer, T.T., Shur-Fen Gau, S., Méndez, L. Montgomery, W. & J.A. Monk (2013). A Systematic Review of Combination Therapy with Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder, Including Patient Characteristics, Treatment Strategies, Effectiveness, and Tolerability review. <i>J Child Adolesc Psychopharmacology</i> , 23(3): 179-193.
Clonidine en methylfenidaat	Off label voor deze combinatie	3	Sallee, F., Connor, D.F. & J.H. Newcorn (2013). A Review of the Rationale and Clinical Utilization of α_2 -Adrenoceptor Agonists for the Treatment of Attention-Deficit/Hyperactivity and Related Disorders, <i>Journal of Child and Adolescent Psychopharmacology</i> , 23(5): 308-319.

Mate van bewijskracht:

Niveau 1: gebaseerd op een systematische review of ten minste twee onafhankelijk van elkaar uitgevoerde ‘gerandomiseerde vergelijkende’ onderzoeken.

Niveau 2: gebaseerd op ten minste twee onafhankelijk van elkaar uitgevoerde ‘gerandomiseerd vergelijkende’ onderzoeken van matige kwaliteit/onvoldoende omvang.

Niveau 3: gebaseerd op een ‘gerandomiseerd vergelijkend’ onderzoek (van matige kwaliteit/onvoldoende omvang) of een niet vergelijkend onderzoek.

Niveau 4: gebaseerd op mening van deskundigen.